Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 274376, 8 pages
http://dx.doi.org/10.1155/2010/274376
Research Article

Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease

1Department of Biology, Indiana University Purdue University at Indianapolis, 723 West Michigan Street, Indianapolis, IN 46202, USA
2Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
3Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
4Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA

Received 20 August 2010; Accepted 11 October 2010

Academic Editor: Lawrence Serfaty

Copyright © 2010 Bonnie L. Blazer-Yost et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Mudaliar, A. R. Chang, and R. R. Henry, “Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications,” Endocrine Practice, vol. 9, no. 5, pp. 406–416, 2003. View at Google Scholar · View at Scopus
  2. J. Karalliedde and R. E. Buckingham, “Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies,” Drug Safety, vol. 30, no. 9, pp. 741–753, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. R. W. Nesto, D. Bell, R. O. Bonow et al., “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association,” Circulation, vol. 108, no. 23, pp. 2941–2948, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, “Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9406–9411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Guan, C. Hao, D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Nofziger, K. K. Brown, C. D. Smith et al., “PPARγ agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line,” American Journal of Physiology, vol. 297, no. 1, pp. F55–F62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. V. E. Torres and P. C. Harris, “Autosomal dominant polycystic kidney disease: the last 3 years,” Kidney International, vol. 76, no. 2, pp. 149–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Patel, R. Chowdhury, and P. Igarashi, “Advances in the pathogenesis and treatment of polycystic kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 18, no. 2, pp. 99–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ye and J. J. Grantham, “The secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease,” The New England Journal of Medicine, vol. 329, no. 5, pp. 310–313, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. C. J. Davidow, R. L. Maser, L. A. Rome, J. P. Calvet, and J. J. Grantham, “The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro,” Kidney International, vol. 50, no. 1, pp. 208–218, 1996. View at Google Scholar · View at Scopus
  11. R. Mangoo-Karim, M. Ye, D. P. Wallace, J. J. Grantham, and L. P. Sullivan, “Anion secretion drives fluid secretion by monolayers of cultured human polycystic cells,” American Journal of Physiology, vol. 269, no. 3, pp. F381–F388, 1995. View at Google Scholar · View at Scopus
  12. M. N. Muchatuta, V. H. Gattone II, F. A. Wltzmann, and B. L. Blazer-Yost, “Structural and functional analyses of liver cysts from the BALB/c-cpk mouse model of polycystic kidney disease,” Experimental Biology and Medicine, vol. 234, no. 1, pp. 17–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Lager, Q. Qian, R. J. Bengal, M. Ishibashi, and V. E. Torres, “The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease,” Kidney International, vol. 59, no. 1, pp. 126–136, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. P. C. Harris, “Molecular basis of polycystic kidney disease: PKD1, PKD2 and PKHD1,” Current Opinion in Nephrology and Hypertension, vol. 11, no. 3, pp. 309–314, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. V. H. Gattone II, X. Wang, P. C. Harris, and V. E. Torres, “Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist,” Nature Medicine, vol. 9, no. 10, pp. 1323–1326, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. V. E. Torres, X. Wang, Q. Qian, S. Somlo, P. C. Harris, and V. H. Gattone II, “Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease,” Nature Medicine, vol. 10, no. 4, pp. 363–364, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. T. V. Masyuk, A. I. Masyuk, V. E. Torres, P. C. Harris, and N. F. Larusso, “Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3,5-cyclic monophosphate,” Gastroenterology, vol. 132, no. 3, pp. 1104–1116, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J. R. Nyengaard, “Stereologic methods and their application in kidney research,” Journal of the American Society of Nephrology, vol. 10, no. 5, pp. 1100–1123, 1999. View at Google Scholar · View at Scopus
  19. L. Cui, L. Aleksandrov, X.-B. Chang et al., “Domain interdependence in the biosynthetic assembly of CFTR,” Journal of Molecular Biology, vol. 365, no. 4, pp. 981–994, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Muto, A. Aiba, Y. Saito et al., “Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant,” Human Molecular Genetics, vol. 11, no. 15, pp. 1731–1742, 2002. View at Google Scholar · View at Scopus
  21. K. L. Raphael, K. A. Strait, P. K. Stricklett et al., “Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease,” American Journal of Nephrology, vol. 30, no. 5, pp. 468–473, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Dai, Y. Liu, C. Mei et al., “Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats,” Clinical Science, vol. 119, pp. 323–333, 2010. View at Google Scholar
  23. S. B. Mason, Y. Liang, R. M. Sinders et al., “Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD,” Anatomical Record, vol. 293, no. 8, pp. 1279–1288, 2010. View at Publisher · View at Google Scholar
  24. G.-Y. Zhang, T. Cheng, M.-H. Zheng et al., “Activation of peroxisome proliferator-activated receptor-γ inhibits transforming growth factor-β1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro,” Archives of Dermatological Research, vol. 301, no. 7, pp. 515–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Genovese, S. Cuzzocrea, R. Di Paola et al., “Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 on bleomycin-induced lung injury,” European Respiratory Journal, vol. 25, no. 2, pp. 225–234, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. E. Milam, V. G. Keshamouni, S. H. Phan et al., “PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis,” American Journal of Physiology, vol. 294, no. 5, pp. L891–L901, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. E. Toblli, M. G. Ferrini, G. Cao, D. Vernet, M. Angerosa, and N. F. Gonzalez-Cadavid, “Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus,” Nephrology Dialysis Transplantation, vol. 24, no. 8, pp. 2384–2391, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Joy, D. S. Gipson, M. Dike et al., “Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 39–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Ohtomo, Y. Izuhara, S. Takizawa et al., “Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model,” Kidney International, vol. 72, no. 12, pp. 1512–1519, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Kawai, T. Masaki, S. Doi et al., “PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β,” Laboratory Investigation, vol. 89, no. 1, pp. 47–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Marra, R. DeFranco, G. Robino et al., “Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis,” World Journal of Gastroenterology, vol. 11, no. 32, pp. 4931–4938, 2005. View at Google Scholar · View at Scopus
  32. I. A. Leclercq, C. Sempoux, P. Stärkel, and Y. Horsmans, “Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats,” Gut, vol. 55, no. 7, pp. 1020–1029, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Marra, “Thiazolidinediones and hepatic fibrosis: don't wait too long,” Gut, vol. 55, no. 7, pp. 917–919, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Belfort, S. A. Harrison, K. Brown et al., “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 355, no. 22, pp. 2297–2307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Li and D. N. Sheppard, “Therapeutic potential of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors in polycystic kidney disease,” BioDrugs, vol. 23, no. 4, pp. 203–216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Yang, N. D. Sonawane, D. Zhao, S. Somlo, and A. S. Verkman, “Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 19, no. 7, pp. 1300–1310, 2008. View at Publisher · View at Google Scholar · View at Scopus